Welcome to our dedicated page for Waldencast plc news (Ticker: WALD), a resource for investors and traders seeking the latest updates and insights on Waldencast plc stock.
Waldencast plc (NASDAQ: WALD) is a global multi-brand beauty and wellness platform built around the Obagi Medical and Milk Makeup brands. Its news flow centers on segment performance, brand initiatives, and platform-level strategic decisions, providing investors and observers with regular insight into how the company executes its brand-led strategy.
Company updates frequently include quarterly and half-year financial results, furnished to the U.S. Securities and Exchange Commission on Form 6-K and summarized in detailed press releases. These communications break out net revenue, adjusted gross profit, and adjusted EBITDA for Waldencast as a whole and for the Obagi Medical and Milk Makeup segments, highlighting trends across channels and geographies as described by the company.
News related to Obagi Medical often covers product and portfolio developments, clinical data, and expansion into aesthetics. Examples include announcements about FDA approval of Obagi-branded hyaluronic acid injectable products, new clinical data on Obagi hyaluronic acid injectables and scalp serum at professional dermatology meetings, and the acquisition of Novaestiq Corp. and U.S. rights to the Saypha injectable line. These items illustrate how Waldencast presents Obagi Medical’s role at the intersection of skincare and medical aesthetics.
Updates about Milk Makeup focus on brand performance in prestige beauty and digital channels, including references to U.S. retail sales trends, expansion into retailers such as Ulta Beauty and Amazon Premium Beauty, and the impact of specific product launches as described in the company’s quarterly commentary.
At the corporate level, Waldencast’s news also addresses strategic reviews and financing actions, such as the announced review of strategic alternatives by the Board of Directors, the sale of the “Obagi” trademark in Japan, and new credit agreements. Readers of the WALD news page can expect a mix of earnings updates, brand-specific developments, clinical and regulatory milestones, and capital structure announcements directly sourced from company press releases and related SEC filings.
Obagi Medical (NASDAQ: WALD) announced a collaboration with DermFx to run the ALOHA Real-World Program for Obagi® saypha® MagIQ™, aiming to translate FDA pivotal trial results into routine med spa practice. The program will use standardized data capture across DermFx’s five Southern California locations and present initial findings internally.
The partnership emphasizes evidence-based rollout, provider training, integrated skincare-injectable protocols, and support for regional practices to evaluate patient outcomes and satisfaction.
Obagi Medical (NASDAQ: WALD) announced a strategic collaboration with Moxie to run the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program, a real-world evidence initiative evaluating saypha MagIQ across Moxie-supported aesthetic practices. Standardized data collection and early results will be shared at industry events.
Obagi Medical (NASDAQ: WALD) launched a two-step Lip Therapy protocol on February 3, 2026: Lip Therapy AHA + PHA Smoothing Micro-Peel ($55) and Soothe & Protect Lip Treatment SPF 30 ($40). The regimen pairs nightly chemical resurfacing with daily hydration and SPF to improve texture, hydration, and fine lines.
Products are available through professional channels now and on Obagi.com beginning February 3, 2026. Consumer perception testing reported immediate and two-week improvements in hydration and appearance.
Obagi Medical (NASDAQ: WALD) announced a collaboration with VIO Med Spa as a launch partner in the ALOHA Program to generate real-world evidence for Obagi® saypha® MagIQ™. The multi-site program will collect standardized clinical and patient-experience data across VIO’s national franchise and begin with 2 days of expert-led VIO University training.
The initiative combines Obagi protocols with VIO’s injectable expertise to evaluate performance, usability, and patient outcomes for the MACRO Core Technology hyaluronic acid filler.
Obagi Medical (NASDAQ: WALD) announced a collaboration with Next Health for the ALOHA Program to generate real-world evidence on Obagi® saypha® MagIQ™. The multi-site evaluation will collect standardized clinical and patient-experience data across Next Health locations and share initial findings at leadership meetings and industry conferences.
The program integrates injectables with holistic wellness protocols to assess performance in longevity-focused clinical settings.
Waldencast (NASDAQ: WALD) brands Obagi Medical and Alpha Aesthetics Partners launched the ALOHA Program to generate real-world evidence for Obagi® saypha® MagIQ™, Obagi’s first FDA‑approved injectable hyaluronic acid filler. Alpha, selected as the ALOHA launch partner, will run a structured, multi-site evaluation across its network (31 locations in 12 states) with standardized data collection. Initial findings will be presented at the upcoming Alpha Summit and shared at industry conferences. The program focuses on clinical performance, patient experience, and integrating Obagi protocols to support providers and consistent outcomes.
Waldencast (NASDAQ: WALD) announced that Obagi Medical has launched the ALOHA Real-World Program with Platinum Dermatology Partners as the initial launch partner to generate real-world evidence for Obagi saypha MagIQ. The program will provide Platinum providers hands-on use of the injectable, standardized data capture across multiple practices, and a structured evaluation of complete Obagi protocols. Initial findings are slated for presentation at Platinum’s annual Summit in Dallas in September 2026 and at key industry conferences to demonstrate real-world outcomes and support the product’s differentiated launch strategy.
Obagi Medical (NASDAQ: WALD) launched the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program on January 21, 2026 to collect structured real‑world, practice‑focused evidence for the rollout of Obagi® saypha® MagIQ™. The product is described as the company's first FDA‑approved injectable hyaluronic acid filler with claimed features including high usable HA content on injection, consistent gel distribution, and predictable injection force and swelling profile. ALOHA will gather standardized injector and practice owner feedback to inform post‑launch education, scientific content, and broader adoption and is positioned to become the largest real‑world evaluation of a newly launched HA injectable.
Waldencast (NASDAQ: WALD) reported Q2 2025 and H1 2025 results and provided a Q3 2025 trading update on Nov 24, 2025. Q2 2025 net revenue was $66.8M (+5.6% YoY) with Adjusted EBITDA margin of 5.0%. H1 2025 net revenue was $132.3M (+0.5% YoY) and net loss was $185.2M, driven by goodwill impairments of $132.1M (Obagi) and $20.0M (Milk Makeup). Q3 2025 net revenue was $67.8M (‑3.4% YoY); Obagi Medical grew to $42.6M (double‑digit) while Milk Makeup declined to $25.2M.
Strategic moves include FDA approval of Obagi Saypha MagIQ filler, acquisition of Novaestiq, sale of Obagi Japan trademark for $82.5M, credit facility refinancing, and a strategic review led by Lazard.
Obagi Medical (NASDAQ: WALD) presented new clinical data at the American Society for Dermatologic Surgery Annual Meeting, Nov 13–16, 2025 in Chicago.
Key highlights: Obagi saypha ChIQ pivotal randomized multicenter trial showed non-inferiority to Juvéderm Voluma XC for midface augmentation with high patient satisfaction and robust safety across diverse skin types; the abstract was selected as a top 10 oral presentation. Interim 3-month data for Nu-Cil BioStim Scalp Serum reported improvements in scalp health and hair appearance. saypha ChIQ is under FDA review; Obagi saypha MagIQ is FDA approved.
FAQ
What is the current stock price of Waldencast plc (WALD)?
What is the market cap of Waldencast plc (WALD)?
